Novartis AG agreed to pay $3.4 billion for eye-disease medicines that Takeda Pharmaceutical Co. is selling to shed debt after its $62 billion acquisition of Shire Plc.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
